Trial
NCT03752177
A Study of LY3415244 in Participants With Advanced Solid Tumors
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Eli Lilly and Company
Collaborators
—
Condition
Solid Tumor
Intervention
LY3415244
Why stopped
The study was terminated during dose escalation after a determination was made that the risk:benefit ratio no longer favored continued evaluation.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-10-22